Amphastar Pharmaceuticals
AMPH
85 hedge funds and large institutions have $234M invested in Amphastar Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 4 closing their positions.
1,222% more call options, than puts
Call options by funds: $304K | Put options by funds: $23K
650% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 4
157% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 14
48% more capital invested
Capital invested by funds: $158M → $234M (+$76M)
44% more funds holding
Funds holding: 59 → 85 (+26)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.5M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.14M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.03M |
| 5 |
Renaissance Technologies
New York
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$11.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$8.18M |
| 4 |
JP Morgan Chase
New York
|
-$2.5M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$1.85M |
AMPH Hedge Fund Activity: Q2 2015 in Review
85 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2015, worth a combined $234M — up 48% from $158M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AMPH positions and 4 closed out — a net gain of 26 holders — while 36 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.5M. The largest seller was Broadfin Capital, cutting an estimated $11.1M.
- 85 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2015, up from 59 in Q1 2015.
- Funds reported $234M of Amphastar Pharmaceuticals stock for Q2 2015, up 48% quarter-over-quarter.
- 30 funds opened new Amphastar Pharmaceuticals positions in Q2 2015 and 4 closed out, a net change of +26 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $27.5M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2015 was Broadfin Capital, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2015.